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ABSTRACT 
Autoantibodies against nucleosomes are considered a hallmark of systemic lupus 
erythematosus (SLE). We compared in patients with proliferative lupus nephritis the 
diagnostic usefulness of a dsDNA-loaded nucleosome ELISA (anti-dsDNA-NcX) with 
ELISAs in which dsDNA or nucleosomes alone were coated. Defined monoclonal anti-DNA, 
anti-histone and nucleosome-specific autoantibodies were used to evaluate the accessibility of 
nucleosomal epitopes in the anti-dsDNA-NcX ELISA. Autoantibody levels were measured in 
these 3 ELISAs in 100 patients with proliferative lupus nephritis (LN) before 
immunosuppressive treatment. Inter-assay comparisons and associations with clinical and 
serological parameters were analysed. The panel of monoclonal antibodies revealed that all 
epitopes were equally accessible in the anti-dsDNA-NcX ELISA as in the two other ELISAs. 
Patients with proliferative lupus nephritis were positive with dsDNA-loaded nucleosomes in 
86%, with DNA in 66% and with nucleosomes in 85%. In a non-lupus disease control group 
these frequencies were 1.6 % (2 out of 128) for both the anti-dsDNA-NcX and the anti-
dsDNA ELISA and 0 % in the anti-nucleosome ELISA. The titers in the anti-dsDNA-NcX 
ELISA  were high in a group of patients with LN that showed absent reactivity in the anti-
DNA or low titers in the anti-nucleosome ELISA. Anti-dsDNA-NcX positivity was associated 
with higher SLEDAI scores within this group. Within nucleosome-based ELISAs, we propose 
the anti-dsDNA-NcX ELISA as the preferred test system. 
Key words: lupus, lupus nephritis, anti-nucleosome, anti-dsDNA, anti-DNA loaded 
nucleosome 
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1. Introduction 
Autoantibodies against chromatin are considered a hallmark of the autoimmune disease 
systemic lupus erythematosus (SLE). Particularly, chromatin containing apoptosis-associated 
post-translational modifications are targeted (Dieker et al. 2007; van Bavel et al. 2009, 2010 
and 2011). It is thought, that a disturbance in apoptosis or the removal of apoptotic cells 
results in persistence of circulating modified chromatin that is able to activate the immune 
system (Dieker et al. 2002; Fransen et al. 2009a; 2009b). This leads to the formation of anti-
chromatin autoantibodies that form immune complexes with the circulating chromatin and can 
deposit in the glomerulus, thereby inciting a severe local inflammation (van der Vlag and 
Berden 2011). Nucleosomes are the basic units of chromatin and consist of double-stranded 
(ds)DNA wrapped around an octamer of histones. Nucleosomes are crucial as driving 
autoantigen in SLE and important initiators for glomerular lesions. Intrarenal perfusion of 
anti-DNA monoclonal antibodies complexed to nucleosomes led to an extensive binding to 
the glomerular basement membrane and proteinuria in contrast to non-complexed 
monoclonals. (Kramers et al.1994). Elution studies from glomeruli of lupus mice revealed that 
anti-nucleosome antibodies were deposited first, later in time followed by anti-dsDNA 
antibodies (van Bruggen et al. 1996). In glomerular deposits in patients with proliferative LN, 
we could identify nucleosomes (van Bruggen et al. 1997). This finding was further 
corroborated by Rekvig and colleagues. With co-localization immunoelectron microscopy, 
nucleosomes were found to be co-localized with in vivo deposited IgG in both murine (Kalaaji 
et al. 2006) and human lupus nephritis (Kalaaji et al. 2007). In a joint endeavour with 
Professor Moh Daha, to whom this special issue of Molecular Immunology is devoted, we 
found that nucleosomes and C1q could bind in vitro to conditionally immortalized human 
glomerular endothelial cells. Bound nucleosomes served as targets for anti-nuclear antibodies 
from patients with SLE. This binding led to activation of the classical pathway of 
5 
 
complement. Anti-C1q antibodies amplified this complement activation (O'Flynn et al. 2011). 
Taken together these data indicate that both nucleosomes and dsDNA are important 
nephritogenic targets in LN. 
 Recently, a new ELISA was described that uses dsDNA coated onto nucleosomes as antigen 
(Biesen et al. 2011). At a specificity of 99% this ELISA (anti-dsDNA-NcX) shows a higher 
sensitivity (59.9%) compared to the anti-dsDNA (35.8% ) and anti-nucleosome ELISA 
(53.6%), as measured in 207 SLE patients, 357 disease controls (162 patients with rheumatoid 
arthritis, 88 patients with Sjögren’s syndrome, 81 patients with systemic sclerosis and 26 
patients with myositis) and 400 healthy donors. 
Our objective for this study was to analyse the possible masking effect of dsDNA loading 
onto nucleosomes on the accessibility of nucleosomal epitopes, by using a panel of well-
defined anti-dsDNA, anti-histone and nucleosome-specific monoclonal autoantibodies (mAb). 
In addition, we compared in patients with proliferative lupus nephritis the antibody reactivity 
in plasma using a coating of DNA-loaded nucleosomes (dsDNA-NcX), dsDNA or 
nucleosomes in ELISA and compared this to the reactivity in 128 non-lupus disease controls. 
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2. Methods 
2.1. Patients 
Plasmas were collected from patients with biopsy-proven proliferative lupus nephritis (at that 
time classified as WHO class III or IV (Churg et al. 1995) included in the first (Grootscholten 
et al. 2006; Arends et al. 2012) or second Dutch Lupus Nephritis Study (Arends et al. 2014). 
All patients fulfilled ≥4 American College of Rheumatology criteria for SLE. Samples at 
study entry were available from 100 patients. Disease activity was measured using the SLE 
disease activity index (SLEDAI) (Bombardier et al. 1992). Activity in the Farr assay and 
levels of complement C3 and C4 were measured routinely in the local diagnostic facility. The 
use of the patients’ plasma was approved by the local ethics committee and by written consent 
from the patients. Patients (n = 128) referred for musculo-skeletal complaints to the Royal 
National Hospital for Rheumatic Diseases in Bath (UK) served as non-lupus disease controls. 
The blood sample was drawn at the first visit. Follow-up revealed various rheumatic diseases 
(rheumatoid or psoriatic arthritis, osteoarthritis, (fibro)myalgia, Raynaud’s phenomenon, 
cutaneous sclerosis, various forms of vasculitis). Patients diagnosed with SLE during follow-
up were excluded.   
2.2. ELISAs 
The anti-dsDNA-NcX, anti-dsDNA and anti-nucleosome ELISA (Euroimmun Medizinische 
Labordiagnostika AG, Lübeck, Germany) were performed as published previously (Biesen et 
al 2011). Briefly, 100 µl of patient samples (diluted 1:200 and 1:500) and positive and 
negative controls supplied by the manufacturer were transferred to pre-coated plates and 
incubated for 30 minutes at room temperature. A standard curve was generated from three 
calibration sera supplied by the manufacturer (10, 100 and 800 international units (IU) for the 
anti-dsDNA-NcX and anti-dsDNA ELISA; and 2, 20 and 200 relative units (RU) for the anti-
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nucleosome ELISA). Subsequently, plates were washed, incubated with peroxidase-labelled 
anti-human IgG (30 minutes), washed again, and incubated (15 minutes) with substrate 
solution. The reaction was stopped with 0.5 M sulphuric acid and the absorbance was 
measured at 450 nm in a microplate reader (Biorad, Veenendaal, The Netherlands). IU and 
RU values were calculated using the respective standard curve. Cut-off values provided by the 
manufacturer were used (100 IU/ml for the anti-dsDNA-NcX and anti-dsDNA ELISA; and 20 
RU/ml for the anti-nucleosome ELISA). The following mAb were tested in a dilution range: 
anti-dsDNA mAbs #36 and #42 (Kramers et al. 1994); anti-histone mAbs #34 (van der 
Heijden et al. 2005), KM-2 (Dieker et al. 2007) and BT164 (van Bavel et al. 2011); 
nucleosome-specific mAbs #32 (Kramers et al. 1994), BT95, BT116, BT124, BT131 and 
BT162 (van Bavel et al. 2010). For detection a peroxidase-labelled anti-mouse IgG(H+L) 
(Southern Biotechnology Associates, Birmingham, U.S.A.) was used. 
 
2.3. Statistical analysis 
Statistical analysis was performed using PASW Statistics 18 (SPSS, Chicago, Illinois, U.S.A.) 
and Graphpad Prism (Graphpad software, San Diego, California, U.S.A.). Correlations were 
studied using Spearman’s rank correlation. Mann-Whitney U test was used to analyse 
differences between groups. A p value <0.05 was regarded as significant. 
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3. Results 
3.1. Effect of dsDNA loading onto nucleosomes on the accessibility of nucleosomal epitopes 
Loading dsDNA onto coated nucleosomes in ELISA may lead to masking of epitopes both on 
dsDNA as well as on the nucleosome. Therefore, we tested the reactivity of a well-
characterised panel of anti-dsDNA, anti-histone and nucleosome-specific monoclonal 
antibodies (mAbs). The effective concentration of the antibody giving 50% of the maximal 
signal (EC50) in the respective anti-dsDNA-NcX, anti-dsDNA and anti-nucleosome ELISA is 
depicted in Figure 1. Anti-DNA mAbs showed similar EC50 values in all three ELISA. Anti-
histone and nucleosome-specific mAbs showed EC50 values in the anti-dsDNA-NcX ELISA 
similar to the anti-nucleosome ELISA, and were, as expected, negative in the anti-dsDNA 
ELISA.  
3.2. Reactivity in ELISA of patients with proliferative lupus nephritis 
We tested plasmas of a cohort of patients with proliferative lupus nephritis before 
immunosuppressive treatment in the anti-dsDNA-NcX, anti-dsDNA and anti-nucleosome 
ELISA (Figure 2a). Of the patients, 86% were positive in the anti-dsDNA-NcX, 85% in the 
anti-nucleosome ELISA, and 66% in the anti-dsDNA ELISA (Figure 2b). Twenty-one 
patients positive in the anti-dsDNA-NcX ELISA were negative in the anti-dsDNA ELISA, 
while 5 patients were negative in the anti-nucleosome ELISA. Only 5 patients being either 
positive in the anti-dsDNA (n=1) or the anti-nucleosome (n=4) ELISA were negative in the 
anti-dsDNA-NcX ELISA. No significant correlation of anti-dsDNA-NcX titers with the 
SLEDAI score was present. We made three groups on the basis of titers in the anti-dsDNA-
NcX ELISA, <300 IU, between 300 and 900 IU and >900 IU (Figure 2c). Remarkably, in the 
2 groups with anti-dsDNA-NcX titers between 300 and 900 IU, and > 900 IU, some patients 
showed much lower reactivity in the anti-dsDNA and/or anti-nucleosome ELISA. Correlation 
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of dsDNA-NcX and nucleosome reactivity showed two distinct populations (Figure 2d). The 
group of patients with a higher dsDNA-NcX reactivity compared to nucleosome reactivity 
showed a higher mean DNA reactivity (P<0.0001; Figure 2e), although some patients were 
negative in the anti-dsDNA ELISA. Higher anti-dsDNA-NcX titers were associated with 
higher SLEDAI scores (p=0.045; Figure 2f) and lower complement C4 levels (p=0.036), but 
not C3 (p=0.083) (both not shown). We found no significant difference between the two 
groups for clinical outcome parameters (Table 1) and no correlation with serum creatinine or 
proteinuria, before treatment or at last follow-up. 
3.3 Reactivity in ELISA of non-lupus disease controls 
In addition, we tested the reactivity of 128 non-lupus control patients, which is also depicted 
in Fig 2A. In both the anti-dsDNA-NcX ELISA and the anti-dsDNA ELISA, 2 of the 128 
patients were positive, while none were positive in the anti-nucleosome ELISA. The 2 
patients positive in both the anti-dsDNA and anti-dsDNA-NcX ELISA were identical and 
diagnosed as adult onset Still's disease and seronegative rheumatoid arthritis. Using this 
control group, we calculated the specificity to be respectively 98.4 % for the anti-dsDNA-
NcX and the anti-dsDNA ELISA and 100 % for the anti-nucleosome ELISA. 
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4. Discussion 
4.1. Accessibility of nucleosomal epitopes 
We tested the anti-dsDNA-NcX ELISA for the accessibility of nucleosomal epitopes using 
defined anti-dsDNA, anti-histone and nucleosome specific mAbs. Their reactivity in the anti-
dsDNA-NcX ELISA was comparable to the reactivity in the anti-dsDNA and/or anti-
nucleosome ELISA. This indicates that the loading of extra dsDNA onto nucleosomes in the 
anti-dsDNA-NcX ELISA does not alter the accessibility of the various nucleosomal epitopes. 
Therefore, it seems that the anti-dsDNA-NcX ELISA system can be used to test all 
specificities of anti-nucleosome c.q. anti-chromatine antibodies (i.e. anti-dsDNA, anti-histone 
and nucleosome-specific antibodies).  
4.2. Comparison of ELISAs 
In patients with proliferative lupus nephritis the prevalence of positivity in the anti-dsDNA-
NcX and anti-nucleosome ELISA was equal (86% and 85% respectively), but higher than in  
the anti-dsDNA ELISA (66%). Twenty-three patients showed significantly higher titers in the 
anti-dsDNA-NcX ELISA compared to the anti-nucleosome ELISA. These patients showed 
also a higher mean titer in the anti-dsDNA ELISA. This suggests that the anti-dsDNA-NcX 
ELISA provides a better antigenic platform for anti-dsDNA autoantibodies than the anti-
nucleosome ELISA. The clinical relevance of a higher reactivity in the anti-dsDNA-NcX 
ELISA was indicated by a significantly higher SLEDAI score and lower C4 levels. Also 
reactivity in the Farr assay tended to be higher (p=0.1). In addition, twenty–one patients 
positive in the anti-dsDNA-NcX ELISA were negative in the anti-dsDNA ELISA, suggesting 
either the presence of nucleosome-specific and/or anti-histone autoantibodies. These 
autoantibodies, additionally detected by the coating of nucleosomes in the ELISA, are 
specifically associated with SLE (Suer et al. 2004, Biesen et al. 2011, van der Vlag and 
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Berden 2011). Positive reactivity in the anti-nucleosome ELISA with a negative result in the 
anti-dsDNA ELISA is more frequently seen in patients with lupus nephritis (van der Vlag and 
Berden 2011). Five patients were negative in the anti-dsDNA-NcX ELISA, but either positive 
in the anti-dsDNA or anti-nucleosome ELISA (fig 2B). Reviewing the clinical charts and the 
laboratory findings, we could not detect common characteristics among these patients. So, we 
cannot explain why these patients tested negative. 
We conclude that in patients with proliferative LN testing with a nucleosome-based ELISA 
has a higher sensitivity than with the anti-dsDNA ELISA, but has equal specificity. This 
higher sensitivity and equal specificity, has also been reported for SLE patients without 
nephritis (reviewed in van der Vlag and Berden 2011).Furthermore, the anti-dsDNA-NcX 
ELISA reveals a group of patients that has low reactivity with nucleosomes and/or dsDNA 
alone, whereas those patients have a significant higher SLEDAI score. Within nucleosome-
based ELISA’s, we propose the anti-dsDNA-NcX ELISA as the preferred test system, since 
we can detect much higher titers if anti-DNA antibodies are present.  
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LEGENDS 
Figure 1. DNA loading of nucleosomes does not mask accessibility of anti-chromatin 
epitopes. Reactivity of a panel of anti-nucleosome mAb in the different ELISAs. Reactivity of 
defined mAbs was tested in the anti-dsDNA-NcX ELISA and compared with the anti-dsDNA 
and anti-nucleosome (Nucl) ELISAs. The effective concentration of the antibody giving 50% 
of the maximal signal (EC50) in the respective ELISA is depicted. The accessibility of tested 
nucleosomal epitopes is not hampered in the anti-dsDNA-NcX ELISA. 
 
Figure 2.  The anti-dsDNA-NcX ELISA reveals higher antibody titers. Plasma reactivity of 
SLE patients (n=100) at onset of proliferative lupus nephritis in anti-dsDNA, anti-nucleosome 
(Nucl) and anti-DNA-loaded nucleosomes (dsDNA-NcX) ELISAs. (a) Plasma samples from 
patients with proliferative lupus nephritis were tested in all three ELISAs. In addition, the 
reactivity of non-lupus disease controls (n=128) was tested. (b) Comparison of plasmas that 
tested positive in the anti-dsDNA-NcX ELISA, the anti-nucleosome and/or anti-dsDNA 
ELISA shown in a Venn diagram. (c) Patients samples were divided in 3 groups based on 
their reactivity in the Anti-dsDNA-NcX ELISA. (d) Correlation of anti-dsDNA-NcX and anti-
nucleosome titers shows two populations of patients. (e) Patients with a higher titers  in the 
anti-dsDNA-NcX ELISA compared to the anti-nucleosome ELISA show a higher mean titer  
in the anti-dsDNA ELISA. (f) Patients with higher titers in the anti-NcX ELISA have a higher 
SLEDAI score. 
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Table 1. Comparison of clinical and laboratory parameters for patients showing equal 
(dsDNA-NcX~Nucl) or higher (dsDNA-NcX>>Nucl) reactivity in the anti-dsDNA-NcX 
ELISA compared to the anti-nucleosome (Nucl) ELISA  
  
dsDNA-
NcX~Nucl 
dsDNA-
NcX>>Nucl 
Patients (n) 41 19 
Age (years) 34.2 (17-59) 35.6 (19-56) 
Female/male 36/5 18/1 
Serum creatinine (µmol/l) 124 (58-472) 131 (67-236) 
Proteinuria (g/24h) 4.4 (0.1-9.2) 3.4 (0.5-6.7) 
Farr assay (U/ml) 304 (0-3000) 846 (13-6940) 
Sustained doubling of serum creatinine (n, %) 3 (7%) 3 (16%) 
Renal relapse (n, %) 8 (20%) 4 (21%) 
Lupus nephritis as 1st manifestation (n, %) 16 (39%) 10 (53%) 
Serum creatinine last follow-up (µmol/l) 99 (51-418) 124 (45-440) 
Proteinuria last follow-up (g/24h) 0.48 (0-2.3) 0.38 (0-1.9) 
Death (n, %) 6 (15%) 2 (11%) 
 
